Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors
Diseases and Conditions Researched
Alcohol Drinking
What is the purpose of this trial?
The primary purpose of the study is to increase our knowledge of receptor function in the brains of people who are heavy drinkers and taking naltrexone (NTX), a medication that has been approved for the treatment of alcohol dependence. Receptors are special molecules in the brain to which other molecules (neurotransmitters) attach during the normal every-day workings of the brain. Drugs can bind to those receptor molecules as well. Recent evidence suggests that kappa opioid receptors (KOR's) may play an important role in alcohol drinking behavior. This study will try to determine if naltrexone's ability to attach to these receptors is related to its effectiveness. We will use PET (positron emission tomography) for this study. PET is a type of imaging device found in nuclear medicine. It is used for tracking the presence of injected radioactive materials in the body.
Participation Guidelines
Gender: Both
Click here for detailed participation information for this trial.
| Sponsor: | Yale University |
|---|---|
| Dates: | June 19, 2012 |
| Last Updated: | June 19, 2012 |
| Study HIC#: | 1011007710 |
| Clinicaltrials.gov ID: | NCT01625611 |
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.